Table 2.
Summary of TGFβ targeting drugs in clinical trials
| Name | Mechanism of action | Cancer type | Clinical trial identifier number | Ovarian cancer patient recruitment | Reference |
|---|---|---|---|---|---|
|
Galunisertib (LY2157299) |
TGFβRI kinase inhibitor | Advanced Hepatocellular carcinoma | NCT02240433 | No | [282] |
|
Fresolimumab (GC10080) |
Anti-TGFβ monoclonal antibody | Advanced malignant melanoma or renal cell carcinoma | NCT00356460 | No | [283] |
| TβM1 | Anti-TGFβ1 monoclonal antibody | Adenocarcinoma of the colon | – | No | [284] |
| NIS793 | Anti TGFβ antibody | Advanced malignancies | NCT02947165 | No | [285] |
| Trabedersen (AP12009 or OT-101) | Synthetic TGFβ2 antisense oligodeoxynucleotide | Glioblastoma multiforme or Anaplastic astrocytoma | NCT00431561 | No | [286] |
| ABBV151 | GARP binding, which interferes with production and release of active TGF β Tregs | Advanced Solid tumors | NCT03821935 | Yes | [287] |
| STM 434 | Soluble receptor ligand trap targeting Activin A |
Ovarian Cancer( granulosa cell tumors) and other Advanced solid tumors |
NCT02262455 | No | [265] |
| AVID200 | TGFβ1 and TGFβ 3 neutralizing antibody | Malignant Solid Tumors | NCT03834662 | No | [288] |
| Vactosertib (TEW-7197) | TGFβR1/ALK5 inhibitor | Advanced solid tumors | NCT02160106 | Yes | [289] |
| PF-03446962 | ALK1 inhibitor | Advanced solid tumors | NCT00557856 | Yes | [290] |
| Bintrafuspalfa (M7824) | Bifunctional fusion protein that sequesters TGFβ and blocks PD-L1 | Non-small cell lung cancer, HER2 positive breast cancer | NCT02517398 | No | [278] |
|
Belagenpumatucel-L (Lucanix) |
TGFβ2 antisense modified non-viral based allogenic tumor cell vaccine | Non-small-cell lung cancer at different stages | NCT00676507 | No | [291] |
| TAG vaccine | Vector co-expressing GM-CSF | Advanced metastatic | NCT00684294 | Yes | [292] |